Status:
UNKNOWN
Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites
Lead Sponsor:
Nanjing PLA General Hospital
Conditions:
Immune Function in Blood
Liver Function in Blood
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in liver cirrhosis patients with refractory ascites are very wretched. The objective of this study is to evaluate...
Eligibility Criteria
Inclusion
- Aged 18\~65 years. Ultrasonographic evidences of cirrhosis. hepatic cirrhosis patients with refractory ascite.
Exclusion
- history of moderate to severe hepatic encephalopathy or variceal bleeding during the last two months before enrolment.
- Prothrombin time is less than 30s. Severe problems in other vital organs(e.g.the heart,renal or lungs). Liver tumor on ultrasonography, CT or MRI examination. Pregnant or lactating women. Imaging evidences of vascular thromboses.
- \-
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01854125
Start Date
May 1 2013
Last Update
May 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinling Hospital
Nanjing, Jiangsu, China, 210002